GAMMA Investing’s Acadia Pharmaceuticals ACAD Stock Holding History

GAMMA Investing’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.5K	Buy	2,985 +402	+16%	+$8.85K	﹤0.01%	2018
2026 Q1	$57.5K	Sell	2,583 -826	-24%	-$19.7K	﹤0.01%	2098
2025 Q4	$91.1K	Buy	3,409 +48	+1%	+$1.15K	﹤0.01%	1646
2025 Q3	$71.7K	Buy	3,361 +690	+26%	+$16.3K	﹤0.01%	1751
2025 Q2	$57.6K	Sell	2,671 -842	-24%	-$15.7K	﹤0.01%	1837
2025 Q1	$58.4K	Buy	3,513 +3,030	+627%	+$55K	﹤0.01%	1688
2024 Q4	$8.86K	Buy	483 +196	+68%	+$3.16K	﹤0.01%	2675
2024 Q3	$4.41K	Buy	287 +119	+71%	+$1.99K	﹤0.01%	2794
2024 Q2	$2.73K	Sell	168 -195	-54%	-$3.15K	﹤0.01%	2791
2024 Q1	$6.71K	Sell	363 -21	-5%	-$520	﹤0.01%	2265
2023 Q4	$9.95K	Buy	+384	New	+$9.17K	﹤0.01%	1906

Other funds holding ACAD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

GAMMA Investing's ACAD Position: Q2 2026 in Review

GAMMA Investing increased its Acadia Pharmaceuticals (ACAD) stake by 16% in Q2 2026, buying an estimated $8.85K and bringing the position to 2,985 shares worth $75.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2018.

GAMMA Investing first reported a position in ACAD in Q4 2023 and has held it in 11 quarters since. The position peaked at $91.1K in Q4 2025. 36 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

GAMMA Investing held 2,985 shares of Acadia Pharmaceuticals worth $75.5K as of Q2 2026.
GAMMA Investing bought 402 Acadia Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
Acadia Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2018 holding.
GAMMA Investing first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
GAMMA Investing's Acadia Pharmaceuticals position peaked at $91.1K in Q4 2025.
36 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.